Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

ELOX Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: September 06, 2023

Report Source: 2023 2nd Quarter Report

Analyst's Ratings for Eloxx Pharmaceuticals Inc (ELOX)

Based on 7 analysts giving stock ratings to Eloxx Pharmaceuticals Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
43
Buy
43
Hold
14
Sell
0
Strong Sell
0
Eloxx Pharmaceuticals Inc

Eloxx Pharmaceuticals Inc. Stock Analysis ELOX

United States Health Care Nano Cap Report:
Eloxx Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of novel ribonucleic acid-modulating drug candidates. The company is headquartered in Watertown, Massachusetts and currently employs 10 full-time employees. The company went IPO on 2012-11-23. The firm is engaged in the science of ribosome modulation, leveraging both its TURBO- ZM chemistry technology platform and its library of aminoglycosides to develop oral small-molecule ribosome modulating agents (RMAs) and eukaryotic ribosome selective glycosides (ERSGs) for the treatment of rare and ultra-rare genetic diseases. Its lead investigational product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. The firm is also advancing ZKN-013 as an oral agent for the treatment of recessive dystrophic (RDEB)/ junctional epidermolysis bullosa (JEB) and familial adenomatous polyposis (FAP) patients with nonsense mutations. The firm also has preclinical programs focused on select rare diseases, including inherited diseases, cancer caused by nonsense mutations, kidney diseases, as well as rare ocular genetic disorders.
Read More

Eloxx Pharmaceuticals Inc (ELOX) Chart

Key Statistics of Eloxx Pharmaceuticals Inc (ELOX)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$10.00$12.05

Today's Open

$11.73

Volume

41.38K

P/E Ratio (TTM)

-

52 Week Range

$0$17.50

Market Cap

1.12M

Avg. Volume

40.67K

Dividend Yield

-

Financial Metrics & Statements of Eloxx Pharmaceuticals Inc (ELOX)

FAQ's for Eloxx Pharmaceuticals Inc (ELOX)

  • According to Musaffa’s Shariah screening methodology, Eloxx Pharmaceuticals Inc (ELOX) is currently classified as NOT HALAL as of September 2023. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Eloxx Pharmaceuticals Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Eloxx Pharmaceuticals Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Eloxx Pharmaceuticals Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Eloxx Pharmaceuticals Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Eloxx Pharmaceuticals Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.